These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 3921078)
1. Pharmacokinetics of valproic acid in volunteers after a single dose study. Bialer M; Hussein Z; Raz I; Abramsky O; Herishanu Y; Pachys F Biopharm Drug Dispos; 1985; 6(1):33-42. PubMed ID: 3921078 [TBL] [Abstract][Full Text] [Related]
2. Accumulation and washout kinetics of valproic acid and its active metabolites. Pollack GM; McHugh WB; Gengo FM; Ermer JC; Shen DD J Clin Pharmacol; 1986; 26(8):668-76. PubMed ID: 3098806 [TBL] [Abstract][Full Text] [Related]
3. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993 [TBL] [Abstract][Full Text] [Related]
4. Valproic acid elimination rate and urinary excretion of its glucuronide conjugate in patients with epilepsy. Yoshida H; Hirozane K; Kimoto H; Hayashi T; Akiyama T; Katayama H; Watanabe M; Yoshitomi H; Kamiya A Biol Pharm Bull; 1999 Jul; 22(7):716-20. PubMed ID: 10443469 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of total and free valproic acid during monotherapy in infants. Herngren L; Lundberg B; Nergårdh A J Neurol; 1991 Sep; 238(6):315-9. PubMed ID: 1940980 [TBL] [Abstract][Full Text] [Related]
6. Disposition of valproic acid in man. Gugler R; Schell A; Eichelbaum M; Fröscher W; Schulz HU Eur J Clin Pharmacol; 1977 Oct; 12(2):125-32. PubMed ID: 336377 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770 [TBL] [Abstract][Full Text] [Related]
8. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Yamamura N; Imura K; Naganuma H; Nishimura K Drug Metab Dispos; 1999 Jun; 27(6):724-30. PubMed ID: 10348803 [TBL] [Abstract][Full Text] [Related]
9. In vivo plasma protein binding interaction between valproic acid and naproxen. Grimaldi R; Lecchini S; Crema F; Perucca E Eur J Drug Metab Pharmacokinet; 1984; 9(4):359-63. PubMed ID: 6442704 [TBL] [Abstract][Full Text] [Related]
10. Urinary metabolites of valproic acid in epileptic patients. Katayama H; Watanabe M; Yoshitomi H; Yoshida H; Kimoto H; Kamiya A; Hayashi T; Akimura T Biol Pharm Bull; 1998 Mar; 21(3):304-7. PubMed ID: 9556166 [TBL] [Abstract][Full Text] [Related]
11. Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates. Tang W; Abbott FS Chem Res Toxicol; 1996 Mar; 9(2):517-26. PubMed ID: 8839057 [TBL] [Abstract][Full Text] [Related]
12. Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. Kumar S; Wong H; Yeung SA; Riggs KW; Abbott FS; Rurak DW Drug Metab Dispos; 2000 Jul; 28(7):845-56. PubMed ID: 10859159 [TBL] [Abstract][Full Text] [Related]
13. Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing. Rapeport WG; Mendelow AD; French G; MacPherson P; Teasdale E; Agnew E; Thompson GG; Brodie MJ Br J Clin Pharmacol; 1983 Oct; 16(4):365-9. PubMed ID: 6414500 [TBL] [Abstract][Full Text] [Related]
14. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid. Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401 [TBL] [Abstract][Full Text] [Related]
15. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. Dickinson RG; Harland RC; Ilias AM; Rodgers RM; Kaufman SN; Lynn RK; Gerber N J Pharmacol Exp Ther; 1979 Dec; 211(3):583-95. PubMed ID: 390116 [TBL] [Abstract][Full Text] [Related]
16. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Hooper WD; Franklin ME; Glue P; Banfield CR; Radwanski E; McLaughlin DB; McIntyre ME; Dickinson RG; Eadie MJ Epilepsia; 1996 Jan; 37(1):91-7. PubMed ID: 8603632 [TBL] [Abstract][Full Text] [Related]
18. Bioavailability of calcium valproate in normal men compared with the free acid and sodium salt. Glazko AJ; Chang T; Daftsios AC; Eiseman I; Smith TC; Buchanan RA Ther Drug Monit; 1983; 5(4):409-17. PubMed ID: 6419419 [TBL] [Abstract][Full Text] [Related]
19. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. Nau H; Rating D; Koch S; Häuser I; Helge H J Pharmacol Exp Ther; 1981 Dec; 219(3):768-77. PubMed ID: 6795343 [TBL] [Abstract][Full Text] [Related]
20. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats. Brouwer KL; Hall ES; Pollack GM Biochem Pharmacol; 1993 Feb; 45(3):735-42. PubMed ID: 8442771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]